Kaken Pharmaceutical Co Ltd 2005 Annual Report
The report presents Kaken's fiscal 2004 performance, with consolidated net sales of ¥74,923 million and net income of ¥3,417 million. It highlights continued investment in regenerative-medicine products based on bFGF alongside endocrine, inflammation, allergy, and infectious-disease development programs. Environmental activities include ISO14001 certification at the Shizuoka production and R&D facilities and a recycling ratio of over 99% for industrial waste.
Company: Kaken Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2005
Type: Annual Report
Pages: 36
Back to company
Kaken Pharmaceutical Co Ltd
Annual Report
The report presents Kaken's fiscal 2004 performance, with consolidated net sales of ¥74,923 million and net income of ¥3,417 million. It highlights continued investment in regenerative-medicine products based on bFGF alongside endocrine, inflammation, allergy, and infectious-disease development programs. Environmental activities include ISO14001 certification at the Shizuoka production and R&D facilities and a recycling ratio of over 99% for industrial waste.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2005
Reporting Period
Apr 1, 2004 - Mar 31, 2005
Fiscal Year
2005
Type
Annual Report
Language
English
Pages
File Size
Standards & Assurance
No data available
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees